RMH - CAR-T Treatment

The Royal Marsden NHS Foundation TrustcontractFind a TenderRef ocds-h6vhtk-05d335Procurement Act 2023SME suitableVCSE suitablepending

Estimated value

Awarded value

£380k

Suppliers

0

Lots

1

1 awarded

Published

24 Oct 2025

Description

CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients. The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team (MDT). The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.

Scope

Reference
ocds-h6vhtk-05d335
Commercial tool
Standalone contract
Particular suitability
Small and medium-sized enterprises (SME)Voluntary, community and social enterprises (VCSE)

Submission & procedure

Procedure
Direct award

Award details

Awarded supplier(s), contract period and value as published in the award notice.

Awarded value

£380k

Award date

Contract start

01 Nov 2025

Contract end

31 Oct 2026